These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 27076760)

  • 41. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
    Bertotti A; Migliardi G; Galimi F; Sassi F; Torti D; Isella C; Corà D; Di Nicolantonio F; Buscarino M; Petti C; Ribero D; Russolillo N; Muratore A; Massucco P; Pisacane A; Molinaro L; Valtorta E; Sartore-Bianchi A; Risio M; Capussotti L; Gambacorta M; Siena S; Medico E; Sapino A; Marsoni S; Comoglio PM; Bardelli A; Trusolino L
    Cancer Discov; 2011 Nov; 1(6):508-23. PubMed ID: 22586653
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent.
    Mutsaers AJ; Francia G; Man S; Lee CR; Ebos JM; Wu Y; Witte L; Berry S; Moore M; Kerbel RS
    Clin Cancer Res; 2009 Apr; 15(7):2397-405. PubMed ID: 19276250
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
    Martinelli E; Troiani T; Morgillo F; Rodolico G; Vitagliano D; Morelli MP; Tuccillo C; Vecchione L; Capasso A; Orditura M; De Vita F; Eckhardt SG; Santoro M; Berrino L; Ciardiello F
    Clin Cancer Res; 2010 Oct; 16(20):4990-5001. PubMed ID: 20810384
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synthesis and initial tumor affinity testing of iodine-123 labelled EGFR-affine agents as potential imaging probes for hormone-refractory prostate cancer.
    Fozing T; Scheuer C; Samnick S
    Eur J Med Chem; 2010 Sep; 45(9):3780-6. PubMed ID: 20538380
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intratumoral distribution of radiolabeled antibody and radioimmunotherapy in experimental liver metastases model of nude mouse.
    Sato N; Saga T; Sakahara H; Yao Z; Nakamoto Y; Zhang M; Kuroki M; Matsuoka Y; Iida Y; Konishi J
    J Nucl Med; 1999 Apr; 40(4):685-92. PubMed ID: 10210230
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A cisplatin‑incorporated liposome that targets the epidermal growth factor receptor enhances radiotherapeutic efficacy without nephrotoxicity.
    Jung J; Jeong SY; Park SS; Shin SH; Ju EJ; Choi J; Park J; Lee JH; Kim I; Suh YA; Hwang JJ; Kuroda S; Lee JS; Song SY; Choi EK
    Int J Oncol; 2015 Mar; 46(3):1268-74. PubMed ID: 25544240
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models.
    Tonra JR; Corcoran E; Deevi DS; Steiner P; Kearney J; Li H; Ludwig DL; Zhu Z; Witte L; Surguladze D; Hicklin DJ
    Anticancer Res; 2009 Jun; 29(6):1999-2007. PubMed ID: 19528458
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synthesis and purification of a toxin-linked conjugate targeting epidermal growth factor receptor in Escherichia coli.
    Ma C; Li Y; Li Z; Huang H; Xu K; Xu H; Bai J; Li X; Zhao G
    Protein Expr Purif; 2012 May; 83(1):1-7. PubMed ID: 22381467
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Weichang'an and 5-fluorouracil suppresses colorectal cancer in a mouse model.
    Tao L; Yang JK; Gu Y; Zhou X; Zhao AG; Zheng J; Zhu YJ
    World J Gastroenterol; 2015 Jan; 21(4):1125-39. PubMed ID: 25632185
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biodistribution, pharmacokinetics and imaging of (188)Re-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model.
    Chen LC; Chang CH; Yu CY; Chang YJ; Hsu WC; Ho CL; Yeh CH; Luo TY; Lee TW; Ting G
    Nucl Med Biol; 2007 May; 34(4):415-23. PubMed ID: 17499731
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preparation of a novel EGFR specific immunotoxin and its efficacy of anti-colorectal cancer in vitro and in vivo.
    Wu S; Deng C; Zhang C; Xiong J; Gu X; Wang Z; Tu J; Xie J
    Clin Transl Oncol; 2021 Aug; 23(8):1549-1560. PubMed ID: 33474678
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein.
    Miao Z; Ren G; Liu H; Jiang L; Cheng Z
    Bioconjug Chem; 2010 May; 21(5):947-54. PubMed ID: 20402512
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
    Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
    Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.
    Balin-Gauthier D; Delord JP; Rochaix P; Mallard V; Thomas F; Hennebelle I; Bugat R; Canal P; Allal C
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):709-18. PubMed ID: 16320055
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The genomic landscape of response to EGFR blockade in colorectal cancer.
    Bertotti A; Papp E; Jones S; Adleff V; Anagnostou V; Lupo B; Sausen M; Phallen J; Hruban CA; Tokheim C; Niknafs N; Nesselbush M; Lytle K; Sassi F; Cottino F; Migliardi G; Zanella ER; Ribero D; Russolillo N; Mellano A; Muratore A; Paraluppi G; Salizzoni M; Marsoni S; Kragh M; Lantto J; Cassingena A; Li QK; Karchin R; Scharpf R; Sartore-Bianchi A; Siena S; Diaz LA; Trusolino L; Velculescu VE
    Nature; 2015 Oct; 526(7572):263-7. PubMed ID: 26416732
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer.
    Reilly RM; Kiarash R; Sandhu J; Lee YW; Cameron RG; Hendler A; Vallis K; Gariépy J
    J Nucl Med; 2000 May; 41(5):903-11. PubMed ID: 10809207
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts.
    Sreeranganathan M; Uthaman S; Sarmento B; Mohan CG; Park IK; Jayakumar R
    Int J Nanomedicine; 2017; 12():7165-7182. PubMed ID: 29033568
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.
    Napolitano S; Martini G; Rinaldi B; Martinelli E; Donniacuo M; Berrino L; Vitagliano D; Morgillo F; Barra G; De Palma R; Merolla F; Ciardiello F; Troiani T
    Clin Cancer Res; 2015 Jul; 21(13):2975-83. PubMed ID: 25838391
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeted radionuclide therapy for lung cancer with iodine-131-labeled peptide in a nude-mouse model.
    Chen Z; Gao H; Li M; Fang S; Li G; Guo L
    Anticancer Drugs; 2017 Jun; 28(5):480-488. PubMed ID: 28379897
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.
    Moroni M; Veronese S; Benvenuti S; Marrapese G; Sartore-Bianchi A; Di Nicolantonio F; Gambacorta M; Siena S; Bardelli A
    Lancet Oncol; 2005 May; 6(5):279-86. PubMed ID: 15863375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.